# Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

> **NCT05164770** · PHASE3 · UNKNOWN · sponsor: **Shandong Provincial Hospital** · enrollment: 160 (estimated)

## Conditions studied

- High Grade B-Cell Lymphoma, Not Otherwise Specified
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
- Diffuse Large B Cell Lymphoma
- B-cell Non Hodgkin Lymphoma
- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
- **DRUG:** R-CHOP; R-DA-EPOCH; R-HD MTX

## Key facts

- **NCT ID:** NCT05164770
- **Lead sponsor:** Shandong Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2021-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05164770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05164770, "Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05164770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*